JP2016531886A - 全身性エリテマトーデス及び／または狼瘡腎炎の予防または治療のための方法 - Google Patents

全身性エリテマトーデス及び／または狼瘡腎炎の予防または治療のための方法 Download PDF

Info

Publication number
JP2016531886A
JP2016531886A JP2016519782A JP2016519782A JP2016531886A JP 2016531886 A JP2016531886 A JP 2016531886A JP 2016519782 A JP2016519782 A JP 2016519782A JP 2016519782 A JP2016519782 A JP 2016519782A JP 2016531886 A JP2016531886 A JP 2016531886A
Authority
JP
Japan
Prior art keywords
compound
treatment
amino
hydrochloride
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016519782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531886A5 (enExample
Inventor
河村　透
透 河村
靖志 藤谷
靖志 藤谷
瀧澤　正之
正之 瀧澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2016531886A publication Critical patent/JP2016531886A/ja
Publication of JP2016531886A5 publication Critical patent/JP2016531886A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016519782A 2013-10-03 2014-10-02 全身性エリテマトーデス及び／または狼瘡腎炎の予防または治療のための方法 Pending JP2016531886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361886403P 2013-10-03 2013-10-03
US61/886,403 2013-10-03
PCT/US2014/058738 WO2015051067A1 (en) 2013-10-03 2014-10-02 Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis

Publications (2)

Publication Number Publication Date
JP2016531886A true JP2016531886A (ja) 2016-10-13
JP2016531886A5 JP2016531886A5 (enExample) 2017-11-02

Family

ID=51842818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016519782A Pending JP2016531886A (ja) 2013-10-03 2014-10-02 全身性エリテマトーデス及び／または狼瘡腎炎の予防または治療のための方法

Country Status (10)

Country Link
US (2) US20160250238A1 (enExample)
EP (1) EP3052105A1 (enExample)
JP (1) JP2016531886A (enExample)
KR (1) KR20160058886A (enExample)
CN (1) CN105705149A (enExample)
BR (1) BR112016007237A2 (enExample)
CA (1) CA2925935A1 (enExample)
EA (1) EA201690686A1 (enExample)
MX (1) MX2016003979A (enExample)
WO (1) WO2015051067A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112423742B (zh) * 2018-06-27 2024-03-19 阿尔杰农制药股份有限公司 使用阿克他利预防或治疗肾纤维化或肾脏疾病
CA3174375A1 (en) * 2020-05-07 2021-11-11 Sukchan Lee Combination therapy of cycloserine and pentoxifylline for the treatment of depression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535759A (ja) * 2007-08-06 2010-11-25 ミレニアム・ファーマシューティカルズ・インコーポレイテッド プロテアソーム阻害剤
JP2011524903A (ja) * 2008-06-17 2011-09-08 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ボロン酸エステル化合物およびその医薬組成物
WO2012119056A1 (en) * 2011-03-03 2012-09-07 Cephalon, Inc. Proteasome inhibitor delanzomib for use in the treatment of lupus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
DE60239384D1 (de) 2001-01-25 2011-04-21 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulierungen von borsäure-verbindungen
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
CA2794334C (en) 2010-03-31 2018-06-12 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
WO2012177835A1 (en) * 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535759A (ja) * 2007-08-06 2010-11-25 ミレニアム・ファーマシューティカルズ・インコーポレイテッド プロテアソーム阻害剤
JP2011524903A (ja) * 2008-06-17 2011-09-08 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ボロン酸エステル化合物およびその医薬組成物
WO2012119056A1 (en) * 2011-03-03 2012-09-07 Cephalon, Inc. Proteasome inhibitor delanzomib for use in the treatment of lupus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS RHEUM., vol. 64, no. 2, JPN6018016772, 2012, pages 493 - 503, ISSN: 0003930210 *
CHEM. BIOL., vol. 19, JPN6018016766, 2012, pages 99 - 115, ISSN: 0003930207 *
DRUGS FUTURE, vol. 37, no. 8, JPN6018016773, 2012, pages 561 - 565, ISSN: 0003930211 *
NAT. MED., vol. 14, no. 7, JPN6018016768, 2008, pages 748 - 755, ISSN: 0003930208 *
NEPHRON EXP. NEPHROL., vol. 120, JPN6018016771, 2012, pages 47 - 58, ISSN: 0003930209 *

Also Published As

Publication number Publication date
WO2015051067A1 (en) 2015-04-09
EA201690686A1 (ru) 2016-08-31
CN105705149A (zh) 2016-06-22
US20160250238A1 (en) 2016-09-01
EP3052105A1 (en) 2016-08-10
CA2925935A1 (en) 2015-04-09
US20180099000A1 (en) 2018-04-12
KR20160058886A (ko) 2016-05-25
MX2016003979A (es) 2016-06-15
BR112016007237A2 (pt) 2017-09-12

Similar Documents

Publication Publication Date Title
EP2759533B1 (en) Condensed heterocyclic compound
JPWO2007123186A1 (ja) 医薬
US20100216871A1 (en) Use of compounds having ccr antagonism
WO2018084230A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
CN106132415A (zh) 具有增加的注射速度的阿立哌唑制剂
JP6207291B2 (ja) 外用剤用組成物
WO2007132825A1 (ja) 医薬
US10738004B2 (en) Cyclic compound
CN103917514B (zh) 治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法
JP2016531886A (ja) 全身性エリテマトーデス及び／または狼瘡腎炎の予防または治療のための方法
US20220193028A1 (en) Therapeutic combinations, liquid pharmaceutical compositions, kits for their preparation, and methods of their use
JP2016222611A (ja) 外用剤用組成物
JP2010529133A (ja) フルオロキノロンを用いて炎症を調節するための組成物と方法
JP2004002402A (ja) Ｃｃｒ拮抗作用を有する化合物の用途
KR20190013847A (ko) 불안 장애를 치료하기 위한 (2S)-1-[4-(3,4-디클로로페닐)피페리딘-1-일]-3-[2-(5-메틸-1,3,4-옥사디아졸-2-일)벤조[b]푸란-4-일옥시]프로판-2-올 또는 그의 대사산물
JP2004002370A (ja) 重症セプシス予防治療剤
KR20070074576A (ko) 사구체 질환 치료제
WO2007123234A1 (ja) 抗てんかん作用増強剤
BR112019004520B1 (pt) Composto, medicamento, e, uso do composto
JP2007099728A (ja) 慢性咳嗽の予防、治療および／または症状改善剤
JP2004256529A (ja) 縮環ピリジン誘導体、その製造法および用途
HK1097752A (en) Methods for preventing antipsychotic-induced weight gain
HK1106694A (en) Methods for preventing antipsychotic-induced weight gain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181130